317 related articles for article (PubMed ID: 18177485)
1. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic receptor tyrosine kinase in leukemia.
Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
[TBL] [Abstract][Full Text] [Related]
3. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
Choudhary C; Olsen JV; Brandts C; Cox J; Reddy PN; Böhmer FD; Gerke V; Schmidt-Arras DE; Berdel WE; Müller-Tidow C; Mann M; Serve H
Mol Cell; 2009 Oct; 36(2):326-39. PubMed ID: 19854140
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies.
Correll PH; Paulson RF; Wei X
Gene; 2006 Jun; 374():26-38. PubMed ID: 16524673
[TBL] [Abstract][Full Text] [Related]
6. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon Y; Schwaller J
Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
[TBL] [Abstract][Full Text] [Related]
7. Selection and growth regulation of genetically modified cells with hapten-specific antibody/receptor tyrosine kinase chimera.
Tanaka K; Kawahara M; Ueda H; Nagamune T
Biotechnol Prog; 2009; 25(4):1138-45. PubMed ID: 19569211
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
9. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
10. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases.
Abella JV; Park M
Am J Physiol Endocrinol Metab; 2009 May; 296(5):E973-84. PubMed ID: 19240253
[TBL] [Abstract][Full Text] [Related]
11. Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
Tan PK; Wang J; Littler PL; Wong KK; Sweetnam TA; Keefe W; Nash NR; Reding EC; Piu F; Brann MR; Schiffer HH
Mol Pharmacol; 2007 Dec; 72(6):1440-6. PubMed ID: 17715395
[TBL] [Abstract][Full Text] [Related]
12. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function.
Mukherjee S; Tessema M; Wandinger-Ness A
Circ Res; 2006 Mar; 98(6):743-56. PubMed ID: 16574915
[TBL] [Abstract][Full Text] [Related]
13. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
14. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization.
Stapleton D; Balan I; Pawson T; Sicheri F
Nat Struct Biol; 1999 Jan; 6(1):44-9. PubMed ID: 9886291
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinases and their activation in melanoma.
Easty DJ; Gray SG; O'Byrne KJ; O'Donnell D; Bennett DC
Pigment Cell Melanoma Res; 2011 Jun; 24(3):446-61. PubMed ID: 21320293
[TBL] [Abstract][Full Text] [Related]
16. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation.
Delcourt N; Bockaert J; Marin P
Trends Pharmacol Sci; 2007 Dec; 28(12):602-7. PubMed ID: 18001849
[TBL] [Abstract][Full Text] [Related]
17. Cellular signaling by fibroblast growth factor receptors.
Eswarakumar VP; Lax I; Schlessinger J
Cytokine Growth Factor Rev; 2005 Apr; 16(2):139-49. PubMed ID: 15863030
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
19. Quantitative mass spectrometry to investigate epidermal growth factor receptor phosphorylation dynamics.
Schuchardt S; Borlak J
Mass Spectrom Rev; 2008; 27(1):51-65. PubMed ID: 18023079
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.
Schmidt-Arras DE; Böhmer A; Markova B; Choudhary C; Serve H; Böhmer FD
Mol Cell Biol; 2005 May; 25(9):3690-703. PubMed ID: 15831474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
